RAPP
Rapport Therapeutics, Inc.
$38.04
-4.73%
2026-05-08
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-9.49
EPS (TTM)
$-2.60
ROE
-28.3%
Profit Margin
0.0%
Debt/Equity
2.29
Price/Book
3.96
Market Cap
$1.92B
Avg Volume (10D)
325K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$40.92
60D Low
$26.01
Avg Volume
344K
Latest Close
$38.04
Get breakout alerts for RAPP
Sign up for Breakout Scanner to receive daily notifications when RAPP triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Rapport Therapeutics, Inc. (RAPP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RAPP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RAPP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.